|ORACEA Capsules Provide Multiple Benefits Over Doxycycline 100 mg2,3||ORACEA Capsules||Doxycycline 100 mg|
Superior GI tolerability compared to 100 mg2
In a head-to-head clinical study, no nausea, diarrhea or vomiting were reported for ORACEA Capsules (vs 17.3%, 4.3% and 4.3% for doxycycline 100 mg)
No evidence of bacterial resistance in a 9-month study3
ORACEA Capsules are precisely formulated (30 mg immediate release/10 mg delayed release) to treat the inﬂammatory lesions associated with rosacea without increasing the risk of antibiotic resistance.
No photosensitivity or vaginal candidiasis reported in controlled clinical studies3
In pivotal clinical studies, the most common treatment-related adverse events (>2%) for ORACEA Capsules were nasopharyngitis (4.8%), diarrhea (4.5%), hypertension (3%), sinusitis (2.6%), and aspartate aminotransferase increase (2.2%).
Offer your patients the benefits of a sub-antimicrobial dose
With fewer overall GI disease (GID) comorbidities vs conventional (50 mg/100 mg) dose doxycycline, the GID event rate for a sub-antimicrobial dose was comparable to no doxycycline4
Association Between GID and Doxycycline Dosage4*
Prevalence of GID was with SD† doxycycline‡ vs CD§ doxycycline 100 mg** 0.62†† (0.58-0.67); P<0.0001
SD doxycycline demonstrated prevalence in GID vs CD doxycycline 50 mg‡‡ 0.80 (0.73-0.88); P<0.0001
GID events were between SD doxycycline and no doxycycline use§§ (P=0.16) 1.05 (0.98-1.12); P=0.16
CD doxycycline*** was to be associated with GID vs no doxycycline use 1.53 (1.48-1.58); P<0.0001
- *A cross-sectional study of individuals with a history of rosacea between 2007-2015 (n=77,177) was conducted to examine the association between doxycycline treatments (40, 50, 100 mg, and no doxycycline) and 10 gastrointestinal diseases4
- †Sub-antimicrobial dose
- ‡Rosacea population aged 30-64 with SD-doxycycline intake (n=4,835).
- §Conventional dose
- **Rosacea population aged 30-64 with CD-doxycycline intake 100 mg intake (n=18,953).
- ††Adjusted odds ratios (aOR) were computed using logistic regression, adjusted for age and sex, and 95% confidence intervals were used
- ‡‡Rosacea population aged 30-64 with CD-doxycycline intake 50 mg intake (n=3,142)
- §§Rosacea population aged 30-64 without CD-doxycycline intake and without SD-doxycycline intake (n=50,492)
- ***Rosacea population aged 30-64 with standard dose (50 or 100 mg), CD-doxycycline intake and without sub-antimicrobial dose, modified release doxycycline intake (n=21,790)
Help your patients see a positive difference
Not actual patients. Individual results may vary. Results are simulated to show average improvement in clinical trials.
IGA (Investigator’s Global Assessment) Scale
4 - Severe
Numerous small and/or large papules/pustules, severe erythema
3 - Moderate
Several small or large papules/pustules, moderate erythema
2 - Mild
Few small papules/pustules, mild
1 - Almost Clear
Very few small papules/pustules, very mild erythema present
0 - Clear
No inflammatory lesions present, no erythema
ORACEA Capsules are precisely formulated (30 mg immediate release/10 mg delayed release) beads to treat the inflammatory lesions associated with rosacea and did not increase the risk of antimicrobial resistance in a 9 month study.